Photodynamic therapy of malignant brain tumours

Experience with intraoperative PDT in 50 patients with malignant supratentorial tumours is reported; in 33 cases the tumour was recurrent. In 45 patients the tumour was a cerebral glioma and in five cases a solitary cerebral metastasis. There were 29 males and 17 females with an age range of 17–73 (mean 48) years. All patients received either haematoporphyrin derivative (HPD) or dihaematoporphyrin ether (DHE) 18–24 h preoperatively. A photoilluminating device, of the authors' design, was coupled to an argon dye pump laser in order to deliver light at 630 nm to a tumour cavity created by radical tumour resection and/or tumour cyst drainage. The total light energy delivered ranged from 440 to 3888 J and the light energy density ranged from 8 to 175 J/cm2. In eight patients a line fibre(s) was used to administer interstitial light as a supplement to the cavitary photoillumination. The additional light dose ranged from 60 to 945 J/cm.There were two postoperative deaths as the consequence of haematoma accumulation in the tumour resection cavity. In three patients neurological function was worse postoperatively and did not recover. Postoperative cerebral oedema was pronounced in some cases and required second craniotomy in two patients (the histology from both showed haemorrhagic necrosis of residual tumour). Four patients developed wound infections; two of these required surgical treatment. Four patients, two of whom were hemiparetic, developed deep vein thrombosis and required anticoagulant therapy. There were no adverse systemic reactions to the administration of either photosensitizer and only three skin photosensitivity reactions.Follow up ranged from 1 to 30 months. In the group of 45 patients with gliomas the death rate per observation year was 0.92 for the interval between PDT and death. For the interval between first diagnosis and death the rate was 0.41 deaths per observation year. The median survival was 8.6 months with a 1 and 2 year actuarial survival rate of 32% and 18%, repectively.In 12 patients a complete or near complete CT scan response was identified post PDT. These patients tended to have a tumour geometry (e.g. cystic) that allowed complete or near complete light distribution to the tumour. The median survival for this group was 17.1 months with a 1 and 2 year actuarial survival of 62% and 38%, respectively. In the 33 cases without a complete response the median survival was 6.5 months with a 1 and 2 year actuarial survival of 22% and 11%, respectively.Photodynamic therapy of malignant brain tumours can be carried out with acceptable risk. Good responses appear to be related to adequate light delivery to the tumour.

[1]  C. Wilson,et al.  Photochemotherapy of glioma cells by visible light and hematoporphyrin. , 1975, Cancer research.

[2]  H. Kostron,et al.  [Photodynamic therapy of malignant brain tumors]. , 1987, Wiener klinische Wochenschrift.

[3]  R. Maniewski,et al.  On the accuracy of source localisation in cardiac measurements. , 1987, Physics in medicine and biology.

[4]  B. Wilson,et al.  Photo-Dynamic Therapy: Cavitary Photo-Illumination of Malignant Cerebral Tumours Using a Laser Coupled Inflatable Balloon , 1985, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[5]  J. H. Kinsey,et al.  Photoradiation therapy in the treatment of malignant brain tumors: a phase I (feasibility) study. , 1981, Neurosurgery.

[6]  C. Gomer,et al.  Observations in studies of quantitative kinetics of tritium labelled hematoporphyrin derivatives (HpDI and HpDII) in the normal and neoplastic rat brain model , 2004, Journal of Neuro-Oncology.

[7]  M. Berns,et al.  Distribution of hematoporphyrin derivative in the rat 9l gliosarcoma brain tumor analyzed by digital video fluorescence microscopy. , 1984, Journal of neurosurgery.

[8]  B. Wilson,et al.  PHOTODYNAMIC THERAPY OF MALIGNANT PRIMARY BRAIN TUMOURS: CLINICAL EFFECTS, POSTOPERATIVE ICP, and LIGHT PENETRATION OF THE BRAIN , 1987, Photochemistry and photobiology.

[9]  Bruce Mielke,et al.  Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report , 1985, Cancer.

[10]  H. Kostron,et al.  PHOTODYNAMIC THERAPY OF MALIGNANT BRAIN TUMORS: CLINICAL and NEUROPATHOLOGICAL RESULTS , 1987, Photochemistry and photobiology.

[11]  G Jori,et al.  Photodynamic therapy of malignant brain tumors: clinical results of, difficulties with, questions about, and future prospects for the neurosurgical applications. , 1988, Neurosurgery.

[12]  C Rivano,et al.  Fast attempts at the photodynamic treatment of human gliomas. , 1980, Journal of neurosurgical sciences.

[13]  E R Laws,et al.  Quantitation of hematoporphyrin derivative in human gliomas, experimental central nervous system tumors, and normal tissues. , 1983, Neurosurgery.

[14]  J. Bailar,et al.  The third national cancer survey , 1969, Ca.

[15]  A H Kaye,et al.  Uptake and retention of hematoporphyrin derivative in an in vivo/in vitro model of cerebral glioma. , 1985, Neurosurgery.

[16]  A. Kaye,et al.  Photoradiation therapy causing selective tumor kill in a rat glioma model. , 1987, Neurosurgery.

[17]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[18]  A. M. Olsen,et al.  The use of a derivative of hematoporphyrin in tumor detection. , 1961 .

[19]  R. Connelly,et al.  Third national cancer survey: incidence data. , 1975, National Cancer Institute monograph.

[20]  P Muller,et al.  Photodynamic therapy of brain tumours--post-operative "field fractionation". , 1991, Journal of photochemistry and photobiology. B, Biology.

[21]  W. Simpson,et al.  Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial , 1982, Cancer.

[22]  K. Shin,et al.  Superfractionation radiation therapy in the treatment of malignant astrocytoma: Preliminary report , 1980 .

[23]  A H Kaye,et al.  Photoradiation therapy and its potential in the management of neurological tumors. , 1988, Journal of neurosurgery.

[24]  B. Wilson,et al.  Instrumentation and light dosimetry for intra-operative photodynamic therapy (PDT) of malignant brain tumours. , 1986, Physics in medicine and biology.

[25]  A. D. Ward,et al.  Phototherapy in malignant brain tumors. , 1984, Progress in clinical and biological research.

[26]  G. Jori,et al.  Photodynamic therapy of malignant brain tumors: clinical results of, difficulties with, questions about, and future prospects for the neurosurgical applications. , 1988, Neurosurgery.

[27]  A H Kaye,et al.  Adjuvant high-dose photoradiation therapy in the treatment of cerebral glioma: a phase 1-2 study. , 1987, Journal of neurosurgery.

[28]  P. Gutin,et al.  Hypoxic cell radiosensitizers in the treatment of malignant brain tumors. , 1980, Neurosurgery.

[29]  Walter G. Gunn Cancer: Principles and Practice of Oncology , 1982 .

[30]  B. Wilson,et al.  An update on the penetration depth of 630 nm light in normal and malignant human brain tissue in vivo. , 1986, Physics in medicine and biology.

[31]  R. Martuza,et al.  Cytotoxicity of human brain tumors by hematoporphyrin derivative. , 1986, Journal of Surgical Research.